viewTissue Regenix Group PLC

Tissue Regenix hails significant milestone as it ships new product line to first customer

The delivery of initial orders for OrthoPure XT comes less than six months after regulatory sign-off and in the face of some stiff headwinds

Tissue Regenix Group PLC -

Tissue Regenix Group PLC (LON:TRX) has said first delivery of its new OrthoPure XT product has taken place with further orders expected to be shipped early next year.

The regenerative medicines specialist noted that this represents a quick turnaround from approval (it received its CE Mark in June) to the sale of the first decellularized tendons.

Interest in Tissue’s technology was such that it landed its first UK order in August with a speciality supplier of orthopaedic and biologic products.

It has since targeted Europe, securing a partner in Poland, and is currently in discussions with other parties.

"Our plan is to establish an initial distribution network for OrthoPure XT and expand as procedural levels return,” said Tissue Regenix chief executive Daniel Lee in a statement.

“This will be a key product for the group in Europe and highlights the need, and demand, for biologic solutions outside of the current US market. It is a testament to the work of our processing and commercial teams that we have secured distribution agreements and delivery of the product has remained on-track despite the challenges presented during 2020," he added.

OrthoPure XT, which incorporates the company’s dCELL technology, is used in knee ligament reconstruction.

Quick facts: Tissue Regenix Group PLC


Price: 0.655 GBX

Market Cap: £46.07 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...


Tissue Regenix delivers first-half results that show a strong recovery as it...

Tissue Regenix Group PLC (AIM:TRX, OTC:TSSNF) CEO Danny Lee and CFO David Cocke joined Proactive's Stephen Gunnion with details of the company's interim results, which show a strong recovery following the coronavirus (COVID-19) pandemic with revenues up 21% in constant currency. Lee telling...

2 weeks, 6 days ago

2 min read